Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease
source: American Journal of Hematology
year: 2016
authors: Shirel T, Hubler CP, Shah R, Mager AB, Koch KL, Sheth D, Uhing MR, Jones CW, Field JJ
summary/abstract:The objective of this study was to test the hypothesis that higher daily opioid dose is associated with the presence and severity of neonatal abstinence syndrome (NAS) in pregnant women with sickle cell disease (SCD). This was a retrospective study of pregnant women with SCD who required opioids. NAS was evaluated using the Finnegan scoring system and classified as none, mild, and severe. Severe NAS was defined as a Finnegan score ≥ 8 on 3 consecutive tests. Thirty-four pregnancies were examined in 30 women with SCD. Higher daily morphine dose was associated with a higher percentage of days in the hospital during pregnancy (P < 0.001). Hospital days contributed disproportionately to daily morphine dose as larger amounts of opioids were administered in the hospital compared to home (P = 0.002). Median maternal oral morphine dose was 416 mg for infants with severe NAS compared with 139 mg for those with mild NAS (P = 0.04). For infants with no NAS, median maternal morphine was 4 mg, significantly less than those with mild NAS (P < 0.001). Infants born to women who used on average >200 mg/day of oral morphine equivalent in the last month of pregnancy had a 13-fold increased risk of severe NAS compared with those who used <200 mg/day. These data demonstrate that higher median daily opioid dose is associated with progressively more severe NAS in pregnant women with SCD. Strategies to decrease pain and avoid hospitalizations are needed to reduce opioid use and NAS.
organization: Medical College of Wisconsin; BloodCenter of WisconsinDOI: 10.1002/ajh.24307
read more full text
Related Content
-
Melanie E. Fields, MD, MSCIDr. Fields practices in the Division of ...
-
Edith Aimiuwu, RGNEdith Aimiuwu was trained as a registere...
-
La Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
-
Today’s Faces of Sickle Cell Disease: John Tisdale, MDFor many years, John Tisdale has been wo...
-
Increased acute care utilization in a prospective cohort of adults with sickle cell diseaseThe ESCAPED (Examining Sickle Cell Acute...
-
Prevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
-
Why do blood types matter? – Natalie S. Hodgehttps://www.youtube.com/watch?v=xfZhb6lm...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.